Seres Therapeutics, Inc. — Director's Dealing 2018

Jan 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2018-01-26

Reporting Person: DesRosier Thomas (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-26	COMMON STOCK	M	10000	—	Acquired	10000	Direct
2018-01-26	COMMON STOCK	S	3475	$11.02	Disposed	6525	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-26	RESTRICTED STOCK UNITS	$	M	10000	Disposed		COMMON STOCK (10000)	Direct
2018-01-30	STOCK OPTION (RIGHT TO BUY)	$10.42	A	80000	Disposed	2028-01-29	COMMON STOCK (80000)	Direct
2018-01-30	STOCK OPTION (RIGHT TO BUY)	$10.42	A	100000	Disposed	2028-01-29	COMMON STOCK (100000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.

F3: This Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

F4: This Option will vest as to one third of the shares on January 30, 2019, one third on January 30, 2020 and one third on January 30, 2021.